Lupin is expecting single digit sales growth in current financial year with sluggish US business likely to impact overall global business of the company. However, the company is anticipating double digit growth in Latin America, South Africa and India. Latin America may grow around mid-to-late 20s in percentage terms, South Africa around 20% and India around 15%.
For the first time in a decade, the company had reported a negative growth in FY18, with net sales dropping to Rs 15,560 crore, a decline of 9% from FY17.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1921.35 |
| Dr. Reddys Labs. | 1371.45 |
| Cipla | 1465.90 |
| Zydus Lifesciences | 1176.20 |
| Lupin | 2516.90 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: